Transient Elevation of Eosinophil and Thymus and Activation-Regulated Chemokine Levels Associated with Cutaneous Adverse Events Due to Nemolizumab: A Case Report
Restricted accessResearch articleFirst published online May, 2026
Transient Elevation of Eosinophil and Thymus and Activation-Regulated Chemokine Levels Associated with Cutaneous Adverse Events Due to Nemolizumab: A Case Report
MimaY, YamamotoM, IozumiK. Cutaneous adverse events following Nemolizumab administration: A review. J Clin Med. 2025; 14(9):3026.
2.
DillonSR, SprecherC, HammondA, et al.Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004; 5(7):752–760.
3.
BilsboroughJ, MudriS, ChadwickE, et al.IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M. J Immunol. 2010; 185(10):6023–6030.
4.
KabashimaK, MatsumuraT, KomazakiH, et al.; Nemolizumab-JP01 Study Group. Trial of Nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020; 383(2):141–150.
5.
SasakiW, SaitoR, SuzukiK, et al.Clinical characteristics and risk factors for cutaneous manifestations associated with Nemolizumab in atopic dermatitis: A multicenter retrospective study in Japan. J Dermatol. 2025; doi: 10.1111/1346-8138.17877
